...
首页> 外文期刊>Journal of Molecular Structure >Synthesis, crystal structure analysis, spectral investigations (NMR, FT-IR, UV), DFT calculations, ADMET studies, molecular docking and anticancer activity of 2-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(2-chlorophenyl)-6-methoxypyridine - A novel potent human topoisomerase II alpha inhibitor
【24h】

Synthesis, crystal structure analysis, spectral investigations (NMR, FT-IR, UV), DFT calculations, ADMET studies, molecular docking and anticancer activity of 2-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(2-chlorophenyl)-6-methoxypyridine - A novel potent human topoisomerase II alpha inhibitor

机译:合成,晶体结构分析,光谱研究(NMR,FT-IR,UV),DFT计算,呼气研究,分子对接和2-(1-苄基-5-甲基-1H-1,2,3-三唑醇的抗癌活性 -4-y1)-4-(2-氯苯基)-6-甲氧基吡啶 - 一种新型效力人拓扑异构酶IIα抑制剂

获取原文
获取原文并翻译 | 示例
           

摘要

Previous research studies confirm that molecules containing 1,2,3-triazole moiety are potential anticancer agents which elevates effectiveness and reduces drug resistance. Present study was aimed to evaluate the anticancer activity of the synthesized novel title compound 2-(1-benzyl-5-methyl-1H-1,2,3-triazol-4-yl)-4-(2-chlorophenyl)-6-methoxypyridine (BTCP). The structural and spectral characteristics of BTCP were studied and compared with DFT results. NBO, HOMO and LUMO energies, Mulliken atomic charges and molecular electrostatic potential surface were investigated. The bioavailability of BTCP was confirmed by pharmacological investigations using Molinspiration and PreADMET online servers. Molecular docking studies verified the inhibitory nature of BTCP against human topoisomerase ll alpha enzyme (1ZXM) over standard drug doxorubicin. MIT assay technique has been employed to study anticancer activity of BTCP with three human cancer cell lines (A549, MDAMB-231, PC-3) along with existing drug doxorubicin. The results of docking and anticancer activity specify that BTCP could be regarded as an alternative anticancer drug. (C) 2018 Elsevier B.V. All rights reserved.
机译:以前的研究研究证实,含有1,2,3-三唑部分的分子是潜在的抗癌剂,其升高有效性并降低耐药性。目前的研究旨在评估合成的新型标题化合物2-(1-苄基-5-甲基-1H-1,2,3-三唑-4-基)-4-(2-氯苯基)-6的抗癌活性 - 甲氧基吡啶(BTCP)。研究了BTCP的结构和光谱特征,并与DFT结果进行了比较。 NBO,HOMO和LUMO能量,Mulliken原子电荷和分子静电潜在表面进行了研究。通过使用莫勒斯吹水剂和普罗德在线服务器的药理学调查证实了BTCP的生物利用度。分子对接研究验证了BTCP对人拓扑异构酶L1αα酶(1ZXM)的抑制性质上标准药物DOXORUBININ。已经采用麻省理工学院测定技术研究BTCP的BTCP抗癌活性与三种人类癌细胞系(A549,MDAMB-231,PC-3)以及现有的药物多柔比星。对接和抗癌活动的结果指定了BTCP可以被视为替代抗癌药物。 (c)2018年elestvier b.v.保留所有权利。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号